Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Dec;56(6):763–773. doi: 10.1038/bjc.1987.285

cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment.

A P Wilson 1, C H Ford 1, C E Newman 1, A Howell 1
PMCID: PMC2002397  PMID: 3435704

Abstract

A study on the in vitro sensitivity of tumour cells from patients with ovarian cancer has been carried out in parallel with a clinical study designed to evaluate the role of high-dose cis-platinum (CIS) as first-line chemotherapy. A total of 50 samples from 102 patients have been successfully cultured and screened for in vitro chemosensitivity to 7 drugs, including CIS. The malignant nature of cells growing in culture was confirmed using a combination of karyology, morphology and immunohistochemical staining with HMFG2. Tumours were graded as sensitive (less than 40% of control 3H-leucine incorporation), intermediate (41-60% of control) or resistant (greater than 61% of control) to CIS. Correlation of in vitro sensitivity to cis-platinum with clinical response to cis-platinum assessed using CT scan and second-look laparotomy, showed positive correlation in 9/11 (89%) patients (8 = S/S; 1 = R/R); positive correlation between in vitro sensitivity to phosphoramide mustard and clinical response was also found in 4/6 patients receiving cyclophosphamide (3 = S/S; 1 = R/R). All patients with sensitive tumours showed a clinical response to cis-platinum. Comparison of cis-platinum sensitivity with sensitivity to phosphoramide mustard and melphalan showed that some tumours were sensitive only to cis-platinum; resistance to cis-platinum and sensitivity to phosphoramide mustard/melphalan was an infrequent occurrence. Some tumours which were resistant to cis-platinum showed sensitivity to adriamycin and bleomycin, particularly those from untreated patients. Sensitivity to 5-fluorouracil and resistance to cis-platinum was found in approximately equal proportions of tumours in both the treated and untreated groups.

Full text

PDF
763

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker F. L., Spitzer G., Ajani J. A., Brock W. A., Lukeman J., Pathak S., Tomasovic B., Thielvoldt D., Williams M., Vines C. Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium. Cancer Res. 1986 Mar;46(3):1263–1274. [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berenbaum M. C. Letter: Predicting response of human cancer to chemotherapy. Lancet. 1974 Nov 9;2(7889):1141–1142. doi: 10.1016/s0140-6736(74)90901-5. [DOI] [PubMed] [Google Scholar]
  4. Bruckner H. W., Cohen C. J., Wallach R. C., Kabakow B., Deppe G., Greenspan E. M., Gusberg S. B., Holland J. F. Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapy. Cancer Treat Rep. 1978 Apr;62(4):555–558. [PubMed] [Google Scholar]
  5. Courtenay V. D., Mills J. An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents. Br J Cancer. 1978 Feb;37(2):261–268. doi: 10.1038/bjc.1978.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Freshney R. I., Paul J., Kane I. M. Assay of anti-cancer drugs in tissue culture: conditions affecting their ability to incorporate 3H-leucine after drug treatment. Br J Cancer. 1975 Jan;31(1):89–99. doi: 10.1038/bjc.1975.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hamburger A. W., Salmon S. E., Kim M. B., Trent J. M., Soehnlen B. J., Alberts D. S., Schmidt H. J. Direct cloning of human ovarian carcinoma cells in agar. Cancer Res. 1978 Oct;38(10):3438–3444. [PubMed] [Google Scholar]
  8. Ioachim H. L., Sabbath M., Andersson B., Barber H. R. Tissue cultures of ovarian carcinomas. Lab Invest. 1974 Oct;31(4):381–390. [PubMed] [Google Scholar]
  9. Kavanagh J. J., Wharton J. T., Rutledge F. N. Continuous-infusion vinblastine for treatment of refractory epithelial carcinoma of the ovary: a phase II trial. Cancer Treat Rep. 1984 Nov;68(11):1417–1418. [PubMed] [Google Scholar]
  10. Mouriquand J., Mouriquand C., Petitpas E., Mermet M. A. Long-term tissue cultures of human pleural effusions: a cytological follow-up. In Vitro. 1978 Jul;14(7):591–600. doi: 10.1007/BF02617918. [DOI] [PubMed] [Google Scholar]
  11. Ozols R. F., Ostchega Y., Curt G., Young R. C. High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol. 1987 Feb;5(2):197–201. doi: 10.1200/JCO.1987.5.2.197. [DOI] [PubMed] [Google Scholar]
  12. Ozols R. F., Speyer J. L., Jenkins J., Myers C. E. Phase II trial of 5-FU administered Ip to patients with refractory ovarian cancer. Cancer Treat Rep. 1984 Oct;68(10):1229–1232. [PubMed] [Google Scholar]
  13. Powers J. F., Sladek N. E. Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats. Cancer Res. 1983 Mar;43(3):1101–1106. [PubMed] [Google Scholar]
  14. Sessa C. European studies with cisplatin and cisplatin analogs in advanced ovarian cancer. Eur J Cancer Clin Oncol. 1986 Nov;22(11):1271–1277. doi: 10.1016/0277-5379(86)90132-x. [DOI] [PubMed] [Google Scholar]
  15. Simmonds A. P., McDonald E. C. Ovarian carcinoma cells in culture: assessment of drug sensitivity by clonogenic assay. Br J Cancer. 1984 Sep;50(3):317–326. doi: 10.1038/bjc.1984.178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Taylor-Papadimitriou J., Peterson J. A., Arklie J., Burchell J., Ceriani R. L., Bodmer W. F. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer. 1981 Jul 15;28(1):17–21. doi: 10.1002/ijc.2910280104. [DOI] [PubMed] [Google Scholar]
  17. Vistica D. T., Von Hoff D. D., Torain B. Uptake of melphalan by human ovarian carcinoma cells and its relationship to the amino acid content of ascitic fluid. Cancer Treat Rep. 1981 Jan-Feb;65(1-2):157–161. [PubMed] [Google Scholar]
  18. Von Hoff D. D., Clark G. M., Stogdill B. J., Sarosdy M. F., O'Brien M. T., Casper J. T., Mattox D. E., Page C. P., Cruz A. B., Sandbach J. F. Prospective clinical trial of a human tumor cloning system. Cancer Res. 1983 Apr;43(4):1926–1931. [PubMed] [Google Scholar]
  19. Whitehead R. H., Hughes L. E. Tissue culture studies of malignant effusions. Br J Cancer. 1975 Oct;32(4):512–518. doi: 10.1038/bjc.1975.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wilson A. P., Ford C. H., Newman C. E., Howell A. A comparison of three assays used for the in vitro chemosensitivity testing of human tumours. Br J Cancer. 1984 Jan;49(1):57–63. doi: 10.1038/bjc.1984.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wilson A. P., Neal F. E. In vitro sensitivity of human ovarian tumours to chemotherapeutic agents. Br J Cancer. 1981 Aug;44(2):189–200. doi: 10.1038/bjc.1981.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wiltshaw E., Kroner T. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep. 1976 Jan;60(1):55–60. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES